Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site © 2019 MORU. Photographer: Prayoon Yuentrakul
Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site

Coordinated by the Menzies School of Health Research (Menzies, Darwin, Australia), the Mahidol Oxford Tropical Medicine Research Unit (MORU, Bangkok, Thailand) and the Eijkman Institute of Molecular Biology (Jakarta, Indonesia), the IMPROV (Improving the Radical Cure of Vivax Malaria) trial involved > 2,000 patients in Ethiopia, Afghanistan, Indonesia and Vietnam and tested the treatment effectiveness of a high-dose 7 day course of primaquine.

Its findings challenge the standard treatment regimen that has been widely used for the last 60 years.

The WHO recommends that patients with P. vivax malaria are treated with antimalarial drugs to clear the parasites in the blood followed by a 14-day course of primaquine to kill the liver hypnozoites and prevent recurrent bouts of malaria.

Associate Senior Clinical Research Fellow Dr Bob Taylor, MORU, says adherence to the standard 14-day regimen is poor.

“Primaquine is the only widely available drug that kills the P. vivax hypnozoites in the liver, but patients often fail to complete the treatment once they feel better. We found that the 7-day high-dose course of primaquine was as effective as the recommended 14-day treatment,” Dr Taylor said.

P. vivax malaria is a major cause of illness in Asia, Oceania, the Horn of Africa, and the Americas. The P. vivax parasites has dormant forms in the liver called hypnozoites, that wake up weeks to months later causing relapses - multiple episodes of malaria that lead to repeated illness and time out of work and school.

Senior Researcher Dr Kamala Thriemer (Menzies) says a shorter treatment prevents multiple episodes of malaria that lead to ill health particularly in young children and pregnant women.

“The shorter, 7 day primaquine regimen worked very well, with very few people having another episode of malaria within 12 months. Although some patients had minor side effects, the drug was generally well tolerated,” Dr Thriemer said.

The study’s principal investigator Prof Ric Price (University of Oxford) said: “Vivax malaria is becoming the predominant cause of malaria in the Asia Pacific. A short course primaquine regimen is much easier to administer and patients are more likely to complete treatment.

“If used widely, this new regimen could help reduce and accelerate the elimination of vivax malaria from the region,” said Prof Price.

Reference

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Taylor et al, The Lancet.

Funders

This research was funded by the: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).

Similar stories

Antimalarial chemoprophylaxis for forest goers could help accelerate malaria elimination in Cambodia

Giving people antimalarials during and after visiting the forest reduced their risk of contracting malaria 6-fold, and could be the missing piece towards eliminating malaria in Asia-Pacific and South America, say Mahidol and Oxford University researchers in a study published in The Lancet Infectious Diseases.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

INTERBIO-21st study findings could help predict infants at risk of obesity

Fetal abdomen growth and the mother’s blood fat metabolites very early in pregnancy influence a child’s weight, body fat, vision and neurodevelopment at 2 years of age

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities

MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.